Moderna's experimental coronavirus vaccine shows promise in early-stage study
Vaccine found to be generally safe and well tolerated in the early-stage study
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.
(Reuters) - Moderna Inc said on Monday its experimental COVID-19 vaccine produced antibodies that could "neutralize" the new coronavirus in patients in a small early stage clinical trial, sending its shares up 25%.
The levels of the antibodies were similar to those in blood samples of people who have recovered from COVID-19, early results from the study conducted by the National Institutes of Health showed.
Participants were given three different doses of the vaccine and Moderna said it saw dose-dependent increase in immunogenicity, the ability to provoke an immune response in the body.
Ticker | Security | Last | Change | Change % |
---|---|---|---|---|
MRNA | MODERNA INC. | 43.47 | +0.72 | +1.68% |
The vaccine, mRNA-1273, was also found to be generally safe and well tolerated in the early-stage study, the drug developer said.
BUFFETT'S BERKSHIRE HATHAWAY DUMPS MUCH OF GOLDMAN STAKE, DESPITE CLAIM
Moderna leads global efforts in developing a vaccine for the new coronavirus and last week, won the U.S. health agency's "fast track" label to speed up the regulatory review. It is looking to begin late-stage trials in July.
CLICK HERE TO READ MORE ON FOX BUSINESS
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)
GET FOX BUSINESS ON THE GO BY CLICKING HERE